Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn about recent paper he and his colleagues authored:
“With so many KRAS targeted drugs entering clinical trials pleased to share our editorial in American Society of Clinical Oncology (ASCO) journal JCO OP.
Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.”
David Waterhouse, Chief Innovation Officer at Oncology-Hematology Care, shared this post on LinkedIn, adding:
“There is no doubt that this class of targeted agents are likely to move into first line NSCLCA treatment. If you are involved in clinical lung cancer research, you want to make sure that such the trial is incorporated into your portfolio.
But, it’s not just going to be just for lung cancer. If anyone knows about tissue agnostic drug development, it is Dr. Subbiah.”
Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer
Authors: Andrew J. Pellatt, Deepak Bhamidipati and Vivek Subbiah
